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Background: Studies in cystic fibrosis (CF) report late attention to advance care planning (ACP). The purpose of this study was to examine ACP
with patients receiving care at US adult CF care programs.
Methods: Chart abstraction was used to examine ACP with adults with CF dying from respiratory failure between 2011 and 2013.
Results: We reviewed 210 deaths among 67 CF care programs. Median age at death was 29 years (range 18–73). Median FEV1 in the year
preceding death was 33% predicted (range 13–100%); 68% had severe lung disease with FEV1 b 40% predicted. ACP was documented for 129
(61%), often during hospitalization (61%). Those with ACP had earlier documentation of treatment preferences, before the last month of life (73%
v. 35%; p = b0.01). Advance directives were completed by 93% of those with ACP versus 75% without (p b 0.01); DNR orders and health care
proxy designation occurred more often for those with ACP. Patients awaiting lung transplant had similar rates of ACP as those who were not (67%
v. 61%; p = 0.55). The frequency of ACP varied significantly among the 29 programs contributing data from four or more deaths.
Conclusions: ACP in CF often occurs late in the disease course. Important decisions default to surrogates when opportunities for ACP are missed.
Provision of ACP varies significantly among adult CF care programs. Careful evaluation of opportunities to enhance ACP and implementation of
recommended approaches may lead to better practices in this important aspect of CF care.
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Advance care planning (ACP) is a communication
process between patients and health care providers intended
to align future medical treatments with goals and wishes of
individual patients [1,2]. Tangible outcomes of ACP include
advance directives, medical orders for scope of treatment, and
appropriate documentation and communication of treatment
preferences.ll rights reserved.
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expectancy due to progressive impairment of lung function.
Respiratory failure is the most common cause of death [3]. The
few published studies addressing ACP in CF suggest that it
often occurs late in the illness course, if at all [4–6]. In one
study, only one-third of adults with CF reported having been
asked about ACP by a health care provider, and a similar
proportion completed an advance directive [7]. Single center
investigations have revealed late or absent ACP and advance
directives, “do not resuscitate” (DNR) orders written at the
very end of life, and a majority of deaths occurring in the
hospital with intensive treatments ongoing until the time of
death [4,6]. While ACP is recommended for people with CF
[8–11], there are currently no formal guidelines for ACP in this
population.
In the US, most CF care is provided in care centers accredited
by the Cystic Fibrosis Foundation (CFF). Multidisciplinary care
teams, including physicians, nurses, social workers, dieticians,
physical therapists, and respiratory therapists, provide coordinat-
ed CF care. While only physicians and licensed practitioners may
formally enter orders for limitations on life-sustaining treatments
that follow fromACP conversations, patients may choose to have
conversations about treatment preferences and future medical
care with any trusted provider within the care center. Much of
CF care in the US is provided under direction of guidelines
[12], but the personal, patient-centered nature of treatment
decision making and lack of formal guidelines for ACP as part
of CF care suggests there may be variation in practice for ACP
with patients among CF care centers.
Previous studies and clinical experience highlight challenges
to ACP, including some that are relatively unique to CF. While
shortened life expectancy [3] might seem to trigger ACP,
variable disease progressionmakes prognostication difficult. Lung
transplant, an option for select patients with advanced disease,
could delay ACP [13]. Family caregivers often participate in
medical decision making; thus, planning may not reflect an
individual’s preferences and important decisions may be deferred
to surrogate decision makers when lung disease progresses more
rapidly than anticipated [5,14,15]. Several multidisciplinary CF
care team members may participate in ACP, but lack of clarity
on the responsible party may delay initiation of the process.
Additionally, while practice standards exist for many aspects of
CF care, there is lack of consensus about appropriate timing of
ACP. To our knowledge, no national study of end-of-life care in
CF has been performed in the United States. We undertook this
study to examine practices for ACP in US-based adult CF care
programs, evaluating these and other potential challenges and
informing opportunities for improvement.
2. Methods
We adapted a web-based chart abstraction tool from the
End-of-Life Chart Review Tool [16] to collect information
about patients who died from complications of CF, including
age, cause, and location of death, conversations about ACP,
and advance directives. The tool was pilot tested at the authors’
institutions and further refined (Appendix 1).We invited all 113 currently accredited US adult CF care
programs to complete a review of the last five CF deaths at
their institutions occurring from 2011 to 2013. One program
reported six deaths, and all were included; many programs had
less than five deaths occur during that time period. Approval for
the study was obtained from the Institutional Review Board at
each participating institution. Programs were offered a $100
stipend by the CFF for each abstraction. A pre-programmed
query in the CFF Patient Registry [17] was used to identify
patients who died within the designated time frame. Patients
under age 18 years were excluded. Patients dying after lung
transplantation (approximately 16% of CF deaths in the US in
this time period(12)) were excluded as their care differs
significantly after the procedure, and many of these patients
have less consistent follow-up with multidisciplinary CF care
teams after transplant. Data from patients with non-respiratory
causes of death were excluded (14 unknown, 7 cirrhosis, 17
unrelated to CF) because their clinical courses were not likely
representative of those of patients dying from progressive lung
disease.
Two researchers (JG and RIC) independently reviewed data
and made recommendations regarding potential data errors,
recoding of data entries, and exclusions from analysis. Discrep-
ancies were reviewed with the research team and final decisions
were made by consensus. For purposes of analysis, we defined
ACP as “documented conversations about treatment preferences
between patients and CF health care providers” and assessed for
tangible outcomes of ACP include advance directives, medical
orders for scope of treatment, and appropriate documentation
and communication of treatment preferences. Conversations
between surrogate decision makers and health care providers
were included in the analysis as “conversations about treatment
preferences” but were not considered ACP even if orders for
limitations on life-sustaining treatments were documented as
these decisions can be made by surrogates when patients are no
longer able to communicate with health care providers.
Summary statistics were used to describe results. Chi-square
tests were used to determine differences between groups, such
as those with and without ACP. A multivariable logistic model
was used to determine whether demographic characteristics
(gender, age, lung function, insurance, and transplant status)
and ACP measures (location of ACP, advance directives, lung
transplant, and palliative care consults) were predictive of
outcomes of timing of ACP and timing of advance directives.
Variables having a probability of b0.20 from bivariate correla-
tions and a variance inflation factor b2.5 (≥2.5 indicates too
many correlations with other variables in the model) were entered
into the model using a web-based logistic regression building tool
[18]. Missing or “not applicable” responses were excluded from
the analysis.
A funnel plot was used to determine whether ACP differed
among CF care programs. The ACP rate for each program
reporting four or more patient deaths was plotted with ACP on
the y-axis and number of deaths on the x-axis. The funnel plot is
a statistical process control method that uses 3-sigma control
limits (p = 0.001) to determine outliers and uses the Wilson
method to account for the small number of deaths per program
Table 1
Demographic information for 210 patients dying from respiratory complications
of CF.
Characteristic Median (range) N (%)
Age in years 29 (18–73)
Age group (from CF annual report)
18–24 years 59 (28%)
25–34 years 80 (38%)
35–44 years 39 (19%)
N44 years 32 (15%)
Female gender 116 (55%)
Insurance
Public/government 133 (64%)
Private 72 (35%)
Uninsured 3 (1%)
Percent predicted FEV1
Lowest past year 22 (11–89)
Highest past year 33 (13–100)
Highest FEV1 and lung disease severity category
Mild (N70% predicted) 5 (2%)
Moderate (40–70% predicted) 60 (30%)
Severe (b40% predicted) 138 (68%)
Lowest FEV1 and lung disease severity category
Mild (N70% predicted) 2 (1%)
Moderate (40–70% predicted) 16 (8%)
Severe (b40% predicted) 184 (91%)
Listed for lung transplant 27 (13%)
Received palliative care or hospice services 94 (46%)
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significantly different in regard to ACP rate than those between
the control limits. Programs with ACP rates lying within the
control limits were considered random variation.
3. Results
Information about 254 patients was submitted by 72 adult
CF care programs (63% of currently accredited US programs).
Data from 44 patients were excluded (Fig. 1), and data from 210
patients from 67 programs were analyzed. Patient demographic
information is displayed in Table 1. Median age at death was
29 years (range 18–73), and 55% of the patients were female. The
median highest forced expiratory volume in one second (FEV1) in
the year preceding death was 33% of predicted (range 13–100%),
and the median lowest FEV1 was 22% of predicted (range
11–89%). Not all patients dying from respiratory complica-
tions of CF had severe lung disease: while 74% of patients
had both highest and lowest FEV1 in the severe lung disease
category (FEV1 b 40% predicted) in the year preceding death,
32%had onlymild tomoderate lung disease based on their highest
FEV1. Twenty-seven patients (13%) were on the transplant wait
list at the time of death. Palliative care or hospice services were
utilized by 94 patients (46%).
Conversations about treatment preferences such as resusci-
tation status were documented for 164 patients overall (78%),
but ACP conversations between patients and health care
providers were documented for just 129 (61%), reflecting
surrogate decision making on behalf of some patients. Reasons
cited for lack of ACP included severe illness precluding patient
participation in decision making, unwillingness of the patient to
discuss disease progression or death, lack of perceived need
for ACP, dissent among patient and family, and dissent among
medical providers about treatment options.Fig. 1. Selection of patients for inclusion in the study.Table 2 lists the ACP variables stratified by the 129 patients
with ACP (61%) and the 81 patients without ACP (39%).
Those with ACP had earlier documentation of treatment
preferences, with 73% of conversations occurring at least
1 month before death versus only 35% of those without ACP
(p b 0.01). Greater involvement of CF care team members,
including physicians, nurses, and social workers, in conversa-
tions about treatment preferences was documented for those
with ACP compared to those without ACP. Nine patients (5%)
received palliative care consults; there was no difference in
involvement of palliative care consultants between those with
and without ACP (Fisher exact test p = 0.11). A majority of
ACP (61%) took place during hospitalization for acute illness.
Patients who participated in ACP were more likely to have
documented an advance directive (93% vs 75%, p b 0.01),
designated a health care proxy (75% vs 61%, p = 0.04), and
established a DNR order (75% vs 49%, p b 0.01).
Multivariate analysis revealed that those dying in the
intensive care unit (ICU) had 2.3 times the odds of a late
conversation about treatment preferences (last month of life)
compared with those dying in another setting (p = 0.048).
These patients also had 3.7 times the odds of a documented
advance directive, specifically a DNR order (p = 0.017).
Those with a late conversation had lower odds of ACP, i.e., a
documented conversation between patient and provider as
opposed to a conversation that involved a surrogate rather than
that patient (OR 0.16, p b 0.01). Age and FEV1 were not
significantly associated with timing of ACP. As noted in
Table 2, 86% of patients had an advance directive prior to
death. Advance directives were documented earlier for older
patients: more than 6 months before death for 46% of those older
Table 2
Conversations about treatment preferences for patients with and without ACP. a ACP is defined as documented conversations between patients and health care
providers.
Total (N = 210) ACP (n = 129) No ACP (n = 81) p-value
Conversation about treatment preferences documented b b0.01
No 32 (15%) – 32 (39%)
Yes 164 (78%) 129(100%) 35 (43%)
Unknown/no response 14 (7%) – 14 (17%)
Timing of conversation b0.01
More than 6 months prior to death 56 (35%) 52 (40%) 4 (11%)
1–6 months prior to death 51 (32%) 43 (33%) 8 (24%)
Less than 1 month prior to death 52 (33%) 30 (23%) 22 (65%)
CF physician involved in conversation b0.01
No 55 (28%) 12 (9%) 43 (64%)
Yes 141 (72%) 117 (91%) 24 (36%)
CF nurse involved in conversation b0.01
No 130 (66%) 70 (54%) 60 (90%)
Yes 66 (34%) 59 (46%) 7 (10%)
CF social worker involved in conversation b0.01
No 99 (51%) 48 (32%) 51 (76%)
Yes 97 (49%) 81 (63%) 16 (24%)
Palliative care consultant involved in conversation b 0.14
No 187 (95%) 121 (94%) 66 (99%)
Yes 9 (5%) 8 (6%) 1 (1%)
Location of conversation 0.86
Hospital admission 98 (61%) 77 (62%) 21 (60%)
Outpatient clinic visit 62 (39%) 48 (38%) 14 (40%)
Advance directive b0.01
No 26 (14%) 9 (8%) 17 (25%)
Yes 162 (86%) 111 (93%) 51 (75%)
Do not resuscitate order b0.01
No 56 (33%) 26 (24%) 30 (51%)
Yes 113 (67%) 84 (76%) 29 (49%)
Health care proxy 0.04
No 51 (30%) 27 (25%) 24 (39%)
Yes 120 (70%) 83 (75%) 37 (61%)
Timing of advance directive 0.26
More than 6 months prior to death 50 (35%) 37 (38%) 13 (28%)
1–6 months prior to death 33 (23%) 24 (25%) 9 (20%)
Less than 1 month prior to death 61 (42%) 37 (38%) 24 (52%)
a “Not documented” not included as category. Missing data or “not applicable” responses were excluded from the analysis.
b Chi-square test p-value reported and verified with Fisher Exact test due to small numbers.
Fig. 2. Funnel plot of advanced care planning rates for 29 centers with 4 or more
deaths. Size of bubble represents number of centers having the same result.
Upper and lower control limits set at 3 sigma.
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younger (OR 2.6; p b 0.01). Severity of lung disease (FEV1) was
not associated with timing of advance directives.
Of 27 patients listed for lung transplant, 21 (78%) died prior
to transplantation, five became medically ineligible, and one
did not complete pre-transplant testing. ACP was documented
for 18 (67%) of those listed for transplant, which was not
significantly different from patients not listed for transplant
(61%; p = 0.055). Completion of advance directives did not
differ by lung transplant status.
Finally, we compared ACP provision between CF care
programs. For the 29 programs that contributed information on
four or more patients dying from respiratory failure, ACP
ranged from zero (no ACP provided) to 100% (ACP provided
to all deceased patients). Fig. 2 shows a funnel plot of ACP.
Programs with no documented ACP and those with all patients
participating in ACP differed significantly from the remaining
programs.
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Our study of ACP for 210 patients at 67 adult CF care
programs who died from respiratory failure between 2011 and
2013 represents the largest national investigation of ACP in CF
to date. We found that 61% of patients had documented ACP,
defined a priori as “conversations about treatment preferences
between patients and health care providers.” ACP occurred
primarily during hospitalization for acute illness and often
involved CF care team members. Patients dying in the ICU had
greater odds of late ACP. Patients with ACP were more likely
to have advance directives, specifically DNR orders and health
care proxies, than those without ACP; older patients completed
advance directives further in advance of death. Lung transplant
status was not associated with ACP or completion of advance
directives. Additionally, we found significant variability in
ACP among programs, with some providing no ACP and others
providing ACP to all patients.
While prior large studies do not exist for proper comparison,
our findings support previous single center studies alluding to
challenges of ACP in CF, some of which are unique to the
disease [4–6]. While CF lung disease is progressive, the course
can be unpredictable, and health care providers are often
uncertain about the ideal timing of conversations about ACP.
Our study substantiates previous reports that not all patients
dying from respiratory failure have advanced lung disease and
that conversations about treatment preferences are often
delayed until episodes of severe illness requiring ICU care.
Shortened life expectancy in CF complicates ACP as patients,
caregivers, and health care providers often struggle emotionally
with the anticipated early mortality.
We found that advance directives were established earlier in
older patients, such that older age may be a trigger for ACP.
Many people with CF rely on family caregivers, and complex
relationships and roles of surrogate decision makers create
further challenges to planning for medical care consistent with
patients’ wishes. The multidisciplinary CF care model allows
for continuity of care with devoted health care providers, but
roles may overlap causing uncertainty about who should
address ACP. While we found variation among programs,
seven of 29 programs contributing data on at least four CF
deaths reported ACP occurring for all patients who died. This
suggests that some adult care programs may have developed a
practice standard to reliably address ACP, but many have not.
As referral for lung transplant is a marker of disease
progression and because of uncertain outcomes of transplant for
individual patients, it should serve as a trigger for ACP.We found
a similar frequency of ACP between those listed and not listed for
transplant at the time of death, which supports the clinical
observation that the decision to pursue transplant may shift
emphasis from comfort and quality of life to medical interven-
tions intended to prolong survival and to achieve transplant. We
found that a majority of patients dying from respiratory failure
were not listed for transplant and, of course, listing for transplant
does not guarantee that suitable donor lungs will become
available in time. We therefore advocate that ACP should be
offered regardless of whether transplant is considered.We suggest that health care providers introduce ACP earlier
in the course of disease and revisit with significant clinical
changes regardless of patient age and with milestones such
as transitioning from pediatric to adult care, the need for
supplemental oxygen, frequent hospitalizations for treatment
of pulmonary exacerbations, and referral for lung transplant.
Close caregiver involvement necessitates careful assessment of
social supports, shared decision making with patients and
caregivers, and identification of surrogate decision makers.
Multidisciplinary teams allow for care coordination, and
psychosocial providers can help to assess and overcome barriers
to ACP.
Evidence-based initiatives are underway to improve ad-
vance care planning in many serious illnesses, for example, the
Medical/Physician Orders for Life Sustaining Treatments
(MOLST/POLST) [20,21]. Indeed, ACP is considered a standard
of care for people with serious illness and its incorporation into
routine CF care, while recommended, is not always followed
because of the challenges described above [9,10,22]. As palliative
care consultation services become more widely available [23],
multidisciplinary CF care teams may wish to form partnerships
with these experts for education and support [8] and for
consultation in complex cases. A recent policy statement from
the American Thoracic Society [22] provides general guidance
for clinicians caring for patients with respiratory diseases. This
and other resources may serve as a framework for development
of CF-specific clinical practice guidelines for ACP and other
aspects of palliative care. Thoughtfully developed guidelines
for ACP in CF could serve as a model in other chronic diseases
lacking a specific framework.
Limitations of our study include the retrospective design and
typical challenges of abstracting data from medical records,
such as missing information, erroneous data recording, and
misinterpretation of chart abstraction tool questions. We
reduced the likelihood of erroneous information through careful
review of data for each patient death by two researchers. Over
half of accredited adult CF care programs in the US participated
in this study, but they may have had a particular interest in ACP
and end-of-life care, thus biasing the results. Information was
collected on deaths that occurred over a relatively short time
period from 2011 to 2013 with the rationale to enhance the
applicability of the results to current practice.
In summary, the results of our study suggest that ACP is
occurring earlier and more often than previously reported.
Nevertheless, the provision of ACP varies among adult CF care
programs. When ACP does take place, it often occurs late in the
course of disease and often during hospitalization for acute
illness. If patients are too ill to be involved in important
treatment decisions, these decisions may default to surrogates, a
fact that further emphasizes the need for earlier ACP. The
complex nature of CF and its variable course in individual
patients calls for repeated attention to treatment preferences that
may change over time. Unique aspects of CF and the structure
of CF care create both challenges and opportunities for ACP.
Developing care guidelines with thoughtful input from key
stakeholders – providers, patients, and family members –
and incorporation of successful practices from programs that
101E.P. Dellon et al. / Journal of Cystic Fibrosis 15 (2016) 96–101systematically address and document ACP may help to reduce
the variability and make ACP standard in CF care.
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